Are Milestone-Based Approaches The Future Of Biopharma And CDMO Partnerships
Are Milestone-Based Approaches The Future Of Biopharma And CDMO Partnerships
Sponsored by:
Sponsored by:
More from Manufacturing
• By
A new IQVIA report highlights how the sector benefits the US through metrics like the economy, employment and health.
• By
Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.
• By
Move by French major aligns with broader industry efforts to localize production amid political pressure, as Trump pushes to onshore manufacturing and hints at easing tariff threats.
• By
As CEO Anderson backs high prices for innovative drugs in Europe
More from Business
Sponsored by:
Delve into the challenges facing the NHS, from rising medicine costs to supply shortages, and how generics and branded generics can provide solutions for a more sustainable healthcare system
Sponsored by:
Access key stats from biotechs on the latest trends impacting oncology R&D, including therapeutic pipelines and clinical trial challenges, AI/ML, and a future outlook on innovation.
Sponsored by:
Gain exclusive insights into the biggest challenges biotechs face in oncology and uncover the latest opportunities to accelerate drug development.
Sponsored by:
Learn about the critical role the right CRO plays in successfully navigating the significant drug development opportunities in Japan.